This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
Scope
This report gives important, expert insight you won’t find in any other source. 22 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for:
- Investors that want to understand past trends impacting the biopharmaceutical industry as well as identifying companies to invest in
- Companies that are interested in entering the biopharmaceutical space and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies lead the industry in the past and how they led
- Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on key areas of AI focus
- Insights on leading AI 'Champion' companies
- Insights on leading AI drugs based on their Sales and Forecasts
- Therapeutic and Indication insights into the AI biopharmaceutical market
Table of Contents
1. AI in Pharma1.1. Impact of AI in Pharma
1.2. Key opinion leaders on AI
1.3. Patent and Job Analytics
2. Pharma AI Champions
2.1. Top AI Champion Companies
2.2. Top AI drugs in development
3. AI Industry Trends
3.1. Most Active Companies in AI Development
3.2. Therapy Areas by Deal Value and Volume
4. AI Pharmaceutical Trends
4.1. Top AI Drug Targets
4.2. Top AI Drug ATC Classifications
4.3. Top Expected AI Drug Launches
4.4. AI Drugs by Development Stage
4.5. Top AI Drug Indications
4.6. Review Designation granting for AI Drugs
4.7. Top AI Drug-specific Likelihood of Approvals
4.8. AI Drug Clinical Trials by sponsor type
5. Key Findings
6 Appendix
6.1. Abbreviations
6.2. Methodology
6.3. Related Reports
6.4. About the Authors
6.5. About the Publisher
6.6. Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sumitomo Pharma Co. Ltd
- BioXcel Therapeutics
- Monte Rosa Therapeutics Inc
- Dayton Therapeutics AG
- Skymount Medical Inc,Praxis Precision Medicines Inc
- Alto Neuroscience Inc
- Lantern Pharma Inc
- Evaxion Biotech A/S
- Relay Therapeutics Inc
- Exscientia Plc
- InSilico Medicine
- Recursion Pharmaceuticals Inc
- Chengdu WestGene Biopharma Co Ltd
- Healx Ltd
- Gubra ApS
- inCerebro Co Ltd
- Aria Pharmaceuticals Inc
- Schrodinger Inc
- Standigm Inc
- Cellix Bio Pvt Ltd
- AbSci Corp
- IBio Inc
- GSK
- Oncotelic Therapeutics Inc
- Endogena Therapeutics Inc
- Poolbeg Pharma Plc
